| Title : ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity - Ait-Tihyaty_2013_Invest.New.Drugs_31_1409 |
| Author(s) : Ait-Tihyaty M , Rachid Z , Larroque-Lombard AL , Jean-Claude BJ |
| Ref : Invest New Drugs , 31 :1409 , 2013 |
| Abstract : Ait-Tihyaty_2013_Invest.New.Drugs_31_1409 |
| ESTHER : Ait-Tihyaty_2013_Invest.New.Drugs_31_1409 |
| PubMedSearch : Ait-Tihyaty_2013_Invest.New.Drugs_31_1409 |
| PubMedID: 23959266 |
Ait-Tihyaty M, Rachid Z, Larroque-Lombard AL, Jean-Claude BJ (2013)
ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity
Invest New Drugs
31 :1409
Ait-Tihyaty M, Rachid Z, Larroque-Lombard AL, Jean-Claude BJ (2013)
Invest New Drugs
31 :1409